

acta endocrino logica

Volume 106

May – August 1984

Copenhagen

CHIEF EDITOR J. STARUP . DENMARK

EDITORS H. M. M. FREY . NORWAY

T. B. van WIMERSMA GREIDANUS . THE NETHERLANDS

C. HAGEN . DENMARK

P. W. JUNGBLUT . FEDERAL REPUBLIC OF GERMANY


TH. LEMARCHAND-BÉRAUD . SWITZERLAND

J.-G. LJUNGGREN . SWEDEN

M. SEPPÄLÄ . FINLAND

CONSULTING EDITOR C. HAMBURGER . DENMARK

Advisory Panel, page V
Contents Vol. 106, page VII
Authors' Index, page XI
Subject Index, page XV



Printed in Denmark
by Bogtrykkeriet Forum
Copenhagen

- Prof. Asbjørn Aakvaag**, Bergen, Norway.
Prof. Kurt Ahrén, Göteborg, Sweden.
Prof. Michael Apostolakis, Thessaloniki, Greece.
Dr. Jørgen Arends, Copenhagen, Denmark.
Prof. Gustav Asboe-Hansen, Hellerup, Denmark.
Dr. Michel L. Aubert, Genève, Switzerland.
Prof. G. M. Besser, London, England.
Prof. Dr. G. Bettendorf, Hamburg, FRG.
Dr. Christian Binder, Gentofte, Denmark.
Prof. S. R. Bloom, London, England.
Prof. J. L. Van den Brande, Utrecht, The Netherlands.
Prof. Dr. M. Breckwoldt, Freiburg, FRG.
Prof. Hans R. Brunner, Lausanne, Switzerland.
Prof. Hans Bürgi, Solothurn, Switzerland.
Prof. Marc Bygdeman, Stockholm, Sweden.
Dr. Anne Grete Byskov, Copenhagen, Denmark.
Dr. Kevin Catt, Bethesda, USA.
Prof. Erol Cerasi, Jerusalem, Israel.
Prof. Tim Chard, London, England.
Dr. William F. Crowley, Jr, Boston, USA.
Prof. Leslie J. DeGroot, Chicago, USA.
Dr. François Delange, Brussels, Belgium.
Dr. Paul Delost, Aubièrre, France.
Dr. Pierre A. Desaulles, Basel, Switzerland.
Prof. Dr. G. Dhom, Homburg-Saar, FRG.
Prof. Dr. E. J. Dorhout Mees, Utrecht, The Netherlands.
Dr. John-Fredrik Dyming, Malmö, Sweden.
Prof. Kristen B. Eik-Nes, Trondheim, Norway.
Dr. Walter Elger, Berlin, FRG.
Prof. Dr. F. Ellendorff, Neustadt, FRG.
Dr. Frantz H. Enzmann, Bad Homburg, FRG.
Dr. Ole Faber, Hørsholm, Denmark.
Dr. Ulla Feldt-Rasmussen, Copenhagen, Denmark.
Dr. Per Fernlund, Malmö, Sweden.
Prof. J. A. Fischer, Zürich, Switzerland.
Prof. H. Fleisch, Bern, Switzerland.
Prof. E. Flückiger, Basel, Switzerland.
Prof. Y. A. Fontaine, Paris, France.
Dr. Maguelone G. Forest, Lyon, France.
Prof. P. Franchimont, Liège, Belgium.
Prof. E. R. Froesch, Zürich, Switzerland.
Dr. Per Ivar Gaarder, Oslo, Norway.
Dr. Fulgencio Gomez, Lausanne, Switzerland.
Dr. Ariel Gordin, Helsinki, Finland.
Prof. Amirav Gordon, Jerusalem, Israel.
Prof. F. C. Greenwood, Honolulu, USA.
Prof. Kerstin Hall, Stockholm, Sweden.
Dr. Johan Halse, Oslo, Norway.
Prof. Dr. J. Hammerstein, Berlin, FRG.
Dr. Kristian F. Hanssen, Oslo, Norway.
Dr. Vidar Hansson, Oslo, Norway.
Dr. Egil Haug, Oslo, Norway.
Dr. H. N. Haugen, Oslo, Norway.
Prof. Chr. Hedinger, Zürich, Switzerland.
Dr. Torbjörn Hillensjö, Göteborg, Sweden.
Dr. Jens Juul Holst, Copenhagen, Denmark.
Prof. Bernt Hökfelt, Malmö, Sweden.
Prof. Howard S. Jacobs, London, England.
Prof. C. Jaffiol, Montpellier, France.
Prof. Dr. Karl H. Jakobs, Heidelberg, FRG.
Prof. Elof D. B. Johansson, Uppsala, Sweden.
Prof. Alfred Jost, Paris, France.
Prof. Dr. Heinrich Karg, Freising-Weihenstephan, FRG.
Dr. Anders Karlsson, Uppsala, Sweden.
Dr. Knud W. Kastrup, Glostrup, Denmark.
Prof. Dr. Rudolf Knuppen, Lübeck, FRG.
Prof. Dr. J. Kracht, Giessen, FRG.
Prof. Dr. Michael Krieg, Bochum, FRG.
Prof. Dr. E. Kuss, München, FRG.
Dr. Claus Kühli, Klampenborg, Denmark.
Prof. Dr. J. Köbberling, Göttingen, FRG.
Prof. Bror-Axel Lamberg, Helsinki, Finland.
Prof. Steven W. J. Lamberts, Rotterdam, The Netherlands.
Prof. Jørgen Falck Larsen, Herlev, Denmark.
Dr. J. J. Legros, Liège, Belgium.
Prof. Marc L'Hermite, Bruxelles, Belgium.
Prof. Bruno Lunenfeld, Tel Hashomer, Israel.
Prof. Dr. Helmut Maske, München, FRG.
Prof. Dr. H. P. Meissner, Homburg-Saar, FRG.
Prof. Gabriela Morreale de Escobar, Madrid, Spain.
Prof. Jürg Müller, Zürich, Switzerland.
Prof. Dr. Friedmund Neumann, Berlin, FRG.
Prof. Maria I. New, New York, USA.
Dr. Karl Olof Nilsson, Malmö, Sweden.
Dr. Nils Norman, Oslo, Norway.
Prof. Dr. Wolfgang Oelkers, Berlin, FRG.
Dr. Risto Pelkonen, Kauniainen, Finland.
Prof. Andrea Prader, Zürich, Switzerland.
Prof. Dr. Hans-Jürgen Quabbe, Berlin, FRG.
Prof. Govind S. Rao, Bonn-Venusberg, FRG.
Dr. G. P. van Rees, Leiden, The Netherlands.
Prof. Jens F. Rehfeld, Copenhagen, Denmark.
Prof. Dr. Horst Schleusener, Berlin, FRG.
Prof. Dr. Helmuth Schmidt, Wiesbaden, FRG.
Dr. Gerard A. Schuiling, Groningen, The Netherlands.
Dr. Nancy B. Schwartz, Chicago, USA.
Prof. Dr. H. U. Schweikert, Bonn, FRG.
Dr. K. Siersbæk-Nielsen, Copenhagen, Denmark.
Prof. Niels Erik Skakkebæk, Hvidovre, Denmark.
Prof. Dr. P. G. Smelik, Amsterdam, The Netherlands.
Dr. Johan A. Sundsfjord, Tromsø, Norway.
Prof. Dr. D. F. Swaab, Amsterdam, The Netherlands.
Prof. Dr. H.-D. Taubert, Frankfurt/M, FRG.
Prof. J. H. H. Thijssen, Utrecht, The Netherlands.
Prof. Dr. Helmut Thomas, Ulm, FRG.
Prof. Niels A. Thorn, Copenhagen, Denmark.

Dr. George Tolis, Athens, Greece.
Prof. Olav Trygstad, Oslo, Norway.
Dr. W. M. G. Tunbridge, Newcastle upon Tyne, England.
Prof. Michel B. Vallotton, Genève, Switzerland.
Prof. Tapani Vanha-Perttula, Kuopio, Finland.
Dr. J. van der Vies, Oss, The Netherlands.
Dr. Hans Vilhardt, Copenhagen, Denmark.
Prof. Dr. H. K. A. Visser, Rotterdam, The Netherlands.
Prof. Dr. K. D. Voigt, Hamburg, FRG.
Prof. Peter Wahlberg, Mariehamn, Finland.
Dr. Jørgen Warberg, Copenhagen, Denmark.

Dr. Jørgen Weeke, Århus, Denmark.
Prof. Dr. Klaus von Werder, München, FRG.
Prof. E. D. Williams, Cardiff, UK.
Prof. Charles B. Wilson, San Francisco, USA.
Prof. Milo Zachmann, Zürich, Switzerland.
Dr. Jürgen Zapf, Zürich, Switzerland.
Prof. G. H. Zeilmaker, Rotterdam, The Netherlands.
Prof. Uriel Zor, Rehovot, Israel.
Dr. Klaus Ølgaard, Copenhagen, Denmark.
Prof. Hans Ørskov, Århus, Denmark.
Prof. Ivar Øye, Oslo, Norway.

Hypothalamus

Donoso A O & Banzan A M: Effects of increase of brain GABA levels on the hypothalamic-pituitary-luteinizing hormone axis in rats 298

Stalla G K, Hartwimmer J, von Werder K & Müller O A: Ovine (o) and human (h) corticotrophin releasing factor (CRF) in man: CRF-stimulation and CRF-immunoreactivity 289

Toutou Y, Fèvre M, Bogdan A, Reinberg A, De Prins J, Beck H & Toutou C: Patterns of plasma melatonin with ageing and mental condition: stability of nyctohemeral rhythms and differences in seasonal variations 145

Vakkuri O, Leppälüoto J & Vuolteenaho O: Development and validation of a melatonin radioimmunoassay using radioiodinated melatonin as tracer 152

Yasuda N, Yasuda Y, Aizawa T, Maruta S & Greer M A: In vivo and in vitro comparisons of biological activities of bovine, ovine and rat CRF (corticotrophin-releasing factor) 158

Pituitary

Boehm N, Plas-Roser S & Aron CI: Prolactin and the control of cycle length in the female rat 188

Eigenmann J E, Patterson D F & Froesch E R: Body size parallels insulin-like growth factor I levels but not growth hormone secretory capacity 448

Glänzer K, Appenheimer M, Krück F, Vetter W & Vetter H: Measurement of 8-arginine-vasopressin by radioimmunoassay 317

Grunt J A, Howard C P, & Daughaday W H: Comparison of growth and somatomedin C responses following growth hormone treatment in children with small-for-date short stature, significant idiopathic short stature and hypopituitarism 168

Hagen C, Nyboe Andersen A & Djursing H: Evidence of altered dopaminergic modulation of Prl, LH, FSH, GH and TSH secretion during chronic partial dopamine receptor blockade in normal women 1

Hagen C, Petersen K, Djursing H & Nyboe Andersen A: Evidence of altered dopaminergic modulation of Prl, LH and TSH secretion in patients with normoprolactinaemic amenorrhoea 8

Heulin M-H, Artur M, Geschier C, Straczek J, Vescovi G, Belleville F, Paysant P & Nabet P: The biological assay of human somatomedin A: improvement by small molecular weight natural molecules 43

Hulting A-L, Hall K & Werner S: Somatomedin A increments are diminished in acromegaly with concomitant hyperprolactinaemia 305

Ishibashi M, Hara T, Tagusagawa Y, Fukushima T, Numata H, Hori T & Yamaji T: Effects of ovine corticotrophin-releasing factor and hydrocortisone on growth hormone secretion by pituitary adenoma cells of acromegaly in culture 443

László F A, Csáti S & Balásperi L: Effect of the vasopressin antagonist d/CH₂/₅Tyr Et/VAVP on the antidiuretic action of exogenous and endogenous vasopressin 52

László F A, Csáti S & Balásperi L: Prevention of hyponatraemia and cerebral oedema by the vasopressin antagonist d/CH₂/₅Tyr/Et/VAVP in rats treated with pitressin tannate 56

McKenna T J, Cunningham S, Culliton M, Daly L, Moore A, Magee F & Smyth P P A: Prolactin in hirsute women: possible roles for androgens in suppressing basal levels, and for oestrogens in enhancing TRH-induced responses 15

Nortier J W R, Croughs R J M, Donker G H, Thijssen J H H & Schwarz F: Changes in plasma GH levels and clinical activity during bromocriptine therapy in acromegaly. The value of predictive tests 175

Nortier J W R, Croughs R J M, Thijssen J H H & Schwarz F: Long-term follow-up of five untreated acromegalic patients 437

Oosterom R, Verleun T, Uitterlinden P, Hackeng W H L, Burbach J P H, Wiegant V M & Lamberts S W J: ACTH and β-endorphin secretion by three corticotrophic adenomas in culture. Effects of culture time, dexamethasone, vasopressin and synthetic corticotrophin releasing factor 21

Perheentupa J, Lakshmanan J, Macaso T & Fisher D A: Growth hormone increases neonatal mouse urine epidermal growth factor 184

Poirier J C, Combarnous Y & Blanc M R: Highly specific antisera against native ovine follitropin (oFSH) obtained from crude antisera by affinity chromatography on solid-phase undissociable lutropin (LH) column 38

Reymond M J, Dale Nansel D, Howard Burrows G, Neaves W B & Porter J C: A new clonal strain of rat pituitary tumour cells: a model for non-regulate secretion of prolactin	159
Schuling G A, Moes H & Koiter T R: Desensitization of the pituitary gland induced in vivo by luteinizing hormone-releasing hormone (LRH) or by the LRH-analogue buserelin does not affect the autonomous secretion of luteinizing hormone and follicle stimulating hormone as observed in vitro	454
Seki K, Uesato T, Kato K & Shima K: Twenty-four hour secretory pattern of prolactin in hyperprolactinaemic patients with pituitary micro- and macroadenomas	433
Vierhapper H, Jörg J, Favre L, Vallotton M B & Waldhäusl W: Comparative therapeutic benefit of indomethacin, hydrochlorothiazide, and acetylsalicylic acid in a patient with nephrogenic diabetes insipidus	311
Wogensen L & Warberg J: Cyclic and diurnal alterations in the response of luteinizing hormone and prolactin to prostaglandin E ₂ during the rat oestrous cycle	30
Thyroid	
Aratan-Spire S, Wolf B & Czernichow P: Effects of hypo- and hyperthyroidism on pancreatic TRH-degrading activity and TRH concentrations in developing rat pancreas	209
Bidey S P, Ryder K, Gaines-Das R, Marshall N J & Ekins R P: A comparison of the bioactivity of human and bovine thyrotrophin preparations, as determined by intracellular cyclic AMP responses of cultured FRTL-5 cells and human thyroid cell monolayers	482
Emmertsen K, Melsen F, Mosekilde L, Lund B, Lund B, Sørensen O H, Charles P & Møller J: Vitamin D levels and trabecular bone remodelling before and after surgery for medullary thyroid carcinoma	346
Hallengren B, Melander A & Thesleff S: Local anaesthesia and immunomodulatory effects of antithyroid drugs	336
Ikeda H, Cheng Chiu S, Kuzuya N, Uchimura H & Nagataki S: Effects of in vivo triiodothyronine and long acting thyroid stimulator (LATS) administration on the in vitro thyroid cAMP response to thyrotrophin and LATS	193
Kjærulff H, Bech K & Bliddal H: Isolation of thyroid stimulating immunoglobulins by affinity chromatography using protein A sepharose	79
Lazarus J H, Burr M L, McGregor A M, Weetman A P, Ludgate M, Woodhead J S & Hall R: The prevalence and progression of autoimmune thyroid disease in the elderly	199
Lio S, Pontecorvi A, Caruso M, Monaco F & D'Armiato M: Transitory subclinical and permanent hypothyroidism in the course of subacute thyroiditis (de Quervain)	67
Naafs M A B, van der Velden P C, Fischer H R A, Koorevaar G, van Duin S, Hackeng W H L, Schopman W & Silberbusch J: Changes in nephrogenous cyclic AMP excretion and plasma cyclic AMP following treatment of hyperthyroidism	477
Ortiz-Caro J, Obregón M J, Pascual A & Jolin T: Decreased T ₄ to T ₃ conversion in tissues of streptozotocin-diabetic rats	86
Perrild H, Feldt-Rasmussen U, Bech K, Ahlgren P & Molholm Hansen J: The differential diagnostic problems in unilateral euthyroid Graves' ophthalmopathy	471
Perrild H, Hegedüs L & Arnung K: Sex related goitrogenic effect of lithium carbonate in healthy young subjects	203
Schaison G, Thomopoulos P, Leguillouzie D, Thomas G & Moatti M: Effects of sodium ipodate and propylthiouracil in athyreotic human subjects, role of triiodothyronine and pituitary thyroxine monodeiodination in thyrotrophin regulation	338
Shiota K, Yoshida K, Noguchi C & Nakayama R: In vitro thyrotrophin release with thyrotrophin-releasing hormone and an analogue, DN-1417	71
Swart S, O'Malley B P, Vora J, Barnett D B & Rosenthal F D: The effects of dopaminergic blockade on serum TSH and prolactin levels in thyrotoxicosis	330
Wajchenberg B L, Tsanaclis A M C & Marino R Jr: TSH-containing pituitary adenoma associated with primary hypothyroidism manifested by amenorrhoea and galactorrhoea	61
Wilkin T J & Casey C: The distribution of immunoglobulin-containing cells in human autoimmune thyroiditis	490
Parathyroid	
Auwerx J, Demedts M & Bouillon R: Altered parathyroid set point to calcium in familial hypocalcaemic hypercalcaemia	215
Balabanov S, Töllner U, Richter H-P, Pohlandt F, Gaedicke G & Teller W M: Immunoreactive parathyroid hormone, calcium, and magnesium in human cerebrospinal fluid	227
Chin Chao C, Brown R D & Deftos L J: Seasonal levels of serum parathyroid hormone, calcitonin and alkaline phosphatase in relation to antler cycles in white-tailed deer	234

Davies M, Adams P H, Lumb G A, Berry J L & Loveridge N: Familial hypocalcaemic hypercalcaemia: evidence for continued enhanced renal tubular reabsorption of calcium following total parathyroidectomy	499
Khoury S & Tucci J R: Urinary and nephrogenous cyclic AMP and renal phosphate handling in normal subjects and patients with parathyroid dysfunction	219

Pancreas

Aratan-Spire S, Wolf B & Czernichow P: Developmental pattern of TRH-degrading activity and TRH content in rat pancreas	102
Groop L, Harno K & Tolppanen E-M: The combination of insulin and sulphonylurea in the treatment of secondary drug failure in patients with type II diabetes	97
Groop L & Tolppanen E-M: Factors influencing beta-cell function and insulin sensitivity in patients with type 2 (non-insulin-dependent) diabetes	505
Heine R J, Ponchner M, Hanning I, Home P D, Brown M, Williams D & Alberti K G M M: A comparison of the effects of semisynthetic human insulin and porcine insulin on transmembrane ion shifts and glucose metabolism during euglycaemic clamping	241
Lindström P: Kinetics of 5-hydroxytryptophan potentiation of glucose-induced insulin release	248
MacFarlane I A, Sheppard M C, Black F G, Gilbey S & Wright A D: The hypothalamic-pituitary-thyroid axis in Type I diabetes: influence of diabetic metabolic control	92
Müller-Esch G, Ball P, Heidlüchel K, Graham Wood W & Scriba P C: Insulin hypoglycaemia test guided by a glucose controlled insulin infusion system	350

Liver

Conte N, Cecchetti M, Manente P, Valmachino G, Roiter I & Pavan P: Calcitonin in hepatoma and cirrhosis	109
---	-----

Gastro-intestinal tract

Rasmusson B: Gastro-intestinal polypeptides in patients treated for medullary carcinoma of the thyroid	112
--	-----

Adrenals

Hamstra W N, Doray D & Dunn J D: The effect of urethane on pituitary-adrenal function of female rats	362
Mannelli M, Maggi M, De Feo M L, Cuomo S, Delitala G, Giusti G & Serio M: Effects of naloxone on catecholamine plasma levels in adult men. A dose-response study	357
Mills E H, Coghlan J P, Denton D A, Spence C D, Whitworth J A & Scoggins B A: The effect of potassium loading and sodium depletion on DOC induced hypertension in sheep	521
Nomura K, Naruse M, Naruse K, Demura H & Shizume K: In vivo evidence of cortisol secretion by aldosterone-producing adenomas	516
Stenström G, Sjöström L & Smith U: Diabetes mellitus in pheochromocytoma. Fasting blood glucose levels before and after surgery in 60 patients with pheochromocytoma	511

Ovaries

Bennegård B, Dennefors B & Hamberger L: Interaction between catecholamines and prostaglandin $F_{2\alpha}$ in human luteolysis	532
de Reviere M M, Viguier-Martinez M C & Mariana J C: FSH, LH and prolactin levels, ovarian follicular development and ovarian responsiveness to FSH in the Snell dwarf mouse	121
Duursma S A, Bijlsma J W J, Van Paassen H C, van Buul-Offers S C & Skottner-Lundin A: Changes in serum somatomedin and growth hormone concentrations after 3 weeks oestrogen substitution in post-menopausal women: a pilot study	527
Farish E, Fletcher C D, Hart D M, Azzawi F A, Abdalla H I & Gray C E: The effects of hormone implants on serum lipoproteins and steroid hormones in bilaterally oophorectomised women	116
Fraser H M & Shaw R W: Effects of chronic luteinizing hormone-releasing hormone agonist treatment on dysfunctional uterine bleeding in the stump-tailed macaque	381
Honjo H, Otsubo K, Yasuda J, Kitawaki J, Okada H, Ohkubo T & Nambara T: Conjugated oestrogen during the menstrual cycle measured by a direct radioimmunoassay with an antiserum prepared against oestradiol-17-glucosiduronate-[C-6]-BSA conjugate	374
Mori T, Saito H, Ohno Y, Irahara M, Hosoi E & Saito S: Evidence for existence of somatostatin-like immunoreactivity with molecular heterogeneity in porcine ovaries	254
Patwardhan V V & Lanthier A: Concentration of cyclic AMP in rabbit ovaries in the preovulatory period after administration of luteinizing hormone or human chorionic gonadotrophin	260

Smith C & Perks A M: The effects of bradykinin on the contractile activity of the isolated rat ovary ... 387

Sogn J, Abrahamsson G & Janson P O: Release of cyclic AMP and progesterone from the isolated perfused luteal ovary of the PMSG treated rat ... 265

Wilks J W: Inhibition of folliculogenesis in the monkey following early follicular phase administration of an LRH agonist ... 538

Zachmann M, Manella B, Eiholzer U, Bucher H & Prader A: Influence of oestrogen in high and low doses on plasma steroid concentrations in girls with tall stature and Turner syndrome ... 368

Uterus

Wiqvist I, Norström A, O'Byrne E & Wiqvist N: Regulatory influence of relaxin on human cervical and uterine connective tissue ... 127

Pregnancy

Andersen J R, Borggaard B, Schroeder E, Olsen E B, Stimpel H & Nyholm H C: The dependence of human decidual prolactin production and secretion on the osmotic environment in vitro ... 405

Gómez F, Monnier B & Lemarchand-Béraud T: Foetal exposure to low doses of cyproterone acetate in the rat leads to functional endocrine abnormalities despite normal sexual morphogenesis ... 411

Pérez-López F R, Robert J & Teijeiro J: Prl, TSH, FSH, β -hCG and oestrial responses to repetitive (triple) LRH/TRH administration in the third trimester of human pregnancy ... 400

Roti E, Robuschi G, Alboni A, Emanuele R, d'Amato L, Gardini E, Salvi M, Dall'Aglio E, Gnudi A & Braverman L E: Inhibition of foetal growth hormone (GH) and thyrotrophin (TSH) secretion after maternal administration of somatostatin ... 393

Schams D & Lahlou-Kassi A: Circulating concentrations of oxytocin during pregnancy in ewes ... 277

Wiqvist I, Norström A & Wiqvist N: Effects of oxytocin on cervical and uterine connective tissue ... 271

Yki-Järvinen H & Wahlström T: Immunohistochemical demonstration of relaxin in the placenta after removal of the corpus luteum ... 544

Testes

Ailenberg M, Bartoov B & Mayevsky A: The effect of testosterone on ram spermatozoa collective motility treated by antimycin A ... 133

Namiki M, Koide T, Okuyama A, Sonoda T, Itatani H, Miyake A, Aono T, Terada N & Matsumoto K: Abnormality of testicular FSH receptors in infertile men ... 548

Miscellaneous

Baxter R C, Martin J I & Handelsman D J: Identification of human semen insulin-like growth factor-I/somatomedin-C immunoreactivity and binding protein ... 420

Das D K, Bandyopadhyay D, Bandyopadhyay S & Neogi A: Thyroid hormone regulation of β -adrenergic receptors and catecholamine sensitive adenylate cyclase in foetal heart ... 569

Hau J, Chemnitz J, Teisner B, Tornehave D & Svendsen P: Induction of murine α -foetoprotein synthesis by oestradiol ... 141

Jones R C: The effect of a luteinizing hormone releasing hormone (LRH) agonist (Wy-40,972), levonorgestrel, danazol and ovariectomy on experimental endometriosis in the rat ... 282

Maruyama Y, Aoki N, Suzuki Y, Sinohara H & Yamamoto T: Variation with age in the levels of sex-steroid-binding plasma protein as determined by radioimmunoassay ... 428

Ralston S H, Cowan R A, Robertson A G, Gardner M D & Boyle I T: Circulating vitamin D metabolites and hypercalcaemia of malignancy ... 556

Sjödén G O J, Johnell O, DeLuca H F & Lindgren J U: Effects of 1α OHD₂ on bone tissue. Studies of 1α OHD₂ and 1α OHD₃ in normal rats and in rats treated with prednisolone ... 564

- Abdalla H I, 116
 Abrahamsson G, 265
 Adams P H, 499
 Ahlgren P, 471
 Ailenberg M, 133
 Aizawa T, 158
 Alberti K G M M, 241
 Alboni A, 393
 d'Amato L, 393
 Andersen J R, 405
 Aoki N, 428
 Aono T, 548
 Appenheimer M, 317
 Aratan-Spire S, 102, 209
 Arning K, 203
 Aron C, 188
 Artur M, 43
 Auwerx J, 215
 Azzawi F A, 116

 Balabanov S, 227
 Baláspiri L, 52, 56
 Ball P, 350
 Bandyopadhyay D, 569
 Bandyopadhyay S, 569
 Banzan A M, 298
 Barnett D B, 330
 Bartoov B, 133
 Baxter R C, 420
 Bech K, 79, 471
 Beck H, 145
 Belleville F, 43
 Bennegård B, 532
 Berry J L, 499
 Bidey S P, 482
 Bijlsma J W J, 527
 Black E G, 92
 Blanc M R, 38
 Bliddal H, 79
 Boehm N, 188
 Bogdan A, 145
 Borggaard B, 405
 Bouillon R, 215
 Boyle I T, 556
 Braverman L E, 393
 Brown M, 241
 Brown R D, 234
 Bucher H, 368
 Burbach J P H, 21

 Burr M L, 199
 Burrows G H, 459
 van Buul-Offers S C, 527

 Caruso M, 67
 Casey C, 490
 Cecchetti M, 109
 Charles P, 346
 Chemnitz J, 141
 Cheng Chiu S, 193
 Chin Chao C, 234
 Coghlan J P, 521
 Combarous Y, 38
 Conte N, 109
 Cowan R A, 556
 Crougns R J M, 175, 437
 Csáti S, 52, 56
 Culliton M, 15
 Cunningham S, 15
 Cuomo S, 357
 Czernichow P, 102, 209

 Dall'Aglio E, 393
 Daly L, 15
 D'Armiento M, 67
 Das D K, 569
 Daughaday W H, 168
 Davies M, 499
 De Feo M L, 357
 Defetos L J, 234
 Delitala G, 357
 DeLuca H F, 564
 Demedts M, 215
 Demura H, 516
 Dennefors B, 532
 Denton D A, 521
 De Prins J, 145
 Djursing H, 1, 8
 Donker G H, 175
 Donoso A O, 298
 Doray D, 362
 van Duin S, 477
 Dunn J D, 362
 Duursma S A, 527

 Eigenmann J E, 448
 Eiholzer U, 368
 Ekins R P, 482
 Emanuele R, 393

 Emmertsen K, 346

 Farish E, 116
 Favre L, 311
 Feldt-Rasmussen U, 471
 Fèvre M, 145
 Fischer H R A, 477
 Fisher D A, 184
 Fletcher C D, 116
 Fraser H M, 381
 Froesch E R, 448
 Fukushima T, 443

 Gaedicke G, 227
 Gaines-Das R, 482
 Gardini E, 393
 Gardner M D, 556
 Geschier C, 43
 Gilbey S, 92
 Giusti G, 357
 Glänzer K, 317
 Gnudi A, 393
 Gómez F, 411
 Graham Wood W, 350
 Gray C E, 116
 Greer M A, 158
 Groop L, 97, 505
 Grunt J A, 168

 Hackeng W H L, 21, 477
 Hagen C, 1, 8
 Hall K, 305
 Hall R, 199
 Hallengren B, 336
 Hamberger L, 532
 Hamstra W N, 362
 Handelsman D J, 420
 Hanning I, 241
 Hara T, 443
 Harno K, 97
 Hart D M, 116
 Hartwimmer J, 289
 Hau J, 141
 Hegedüs L, 203
 Heidbüchel K, 350
 Heine R J, 241
 Heulin M-H, 43
 Home P D, 241
 Honjo H, 374

- Hori T, 443
Hosoi E, 254
Howard C P, 168
Hulting A-L, 305
- Ikeda H, 193
Irahara M, 254
Ishibashi M, 443
Itatani H, 548
- Janson P O, 265
Jörg J, 311
Johnell O, 564
Jolin T, 86
Jones R C, 282
- Kato K, 433
Khoury S, 219
Kitawaki J, 374
Kjærulff H, 79
Koide T, 548
Koiter T R, 454
Koorevaar G, 477
Krück F, 317
Kuzuya N, 193
- Lahlou-Kassi A, 277
Lakshmanan J, 184
Lamberts S W J, 21
Lanthier A, 260
László F A, 52, 56
Lazarus J H, 199
Leguillouzic D, 338
Lemarchand-Béraud T, 411
Leppäluoto J, 152
Lindgren J U, 564
Lindström P, 248
Lio S, 67
Loveridge N, 499
Ludgate M, 199
Lumb G A, 499
Lund Bi, 346
Lund Bj, 346
- Macaso T, 184
MacFarlane I A, 92
Maggi M, 357
Magie F, 15
Manella B, 368
Manente P, 109
Mannelli M, 357
Mariana J C, 121
Marino R Jr, 61
Marshall N J, 482
Martin J L, 420
Maruta S, 158
Maruyama Y, 428
- Matsumoto K, 548
Mayevsky A, 133
McGregor A M, 199
McKenna T J, 15
Melander A, 336
Melsen F, 346
Mills F H, 521
Miyake A, 548
Moatti M, 338
Moes H, 454
Monaco F, 67
Mommier B, 411
Moore A, 15
Mori T, 254
Mosekilde L, 346
Müller O A, 289
Müller-Esch G, 350
Mølholm Hansen J, 471
Møller J, 346
- Naafs M A B, 477
Nabet P, 43
Nagataki S, 193
Nakayama R, 71
Nambara T, 374
Namiki M, 548
Nansel D D, 459
Naruse K, 516
Naruse M, 516
Neaves W B, 459
Neogi A, 569
Noguchi C, 71
Nomura K, 516
Norström A, 127, 271
Nortier J W R, 175, 437
Numata H, 443
Nyboe Andersen A, 1, 8
Nyholm H C, 405
- Obregón M J, 86
O'Byrne E, 127
Ohkubo T, 374
Ohno Y, 254
Okada H, 374
Okuyama A, 548
Olsen E B, 405
O'Malley B P, 330
Oosterom R, 21
Ortiz-Caro J, 86
Otsubo K, 374
- Van Paassen H C, 527
Pascual A, 86
Patterson D F, 448
Patwardhan V V, 260
Pavan P, 109
Paysant P, 43
- Pérez-López F R, 400
Perheentupa J, 184
Perks A M, 387
Perrild H, 203, 471
Petersen K, 8
Plas-Roser S, 188
Pohlandt F, 227
Poirier J C, 38
Ponchner M, 241
Pontecorvi A, 67
Porter J C, 459
Prader A, 368
De Prins J, 145
- Ralston S H, 556
Rasmusson B, 112
Reinberg A, 145
de Reviers M M, 121
Reymond J M, 459
Richter H-P, 227
Robert J, 400
Robertson A G, 556
Robuschi G, 393
Roiter I, 109
Rosenthal F D, 330
Roti E, 393
Ryder K, 482
Rye Andersen J, 405
- Saito H, 254
Saito S, 254
Salvi M, 393
Schaison G, 338
Schams D, 277
Schopman W, 477
Schroeder E, 405
Schuiling G A, 454
Schwarz F, 175, 437
Scoggins B A, 521
Scriba P C, 350
Seki K, 433
Serio M, 357
Shaw R W, 381
Sheppard M C, 92
Shima K, 433
Shiota K, 71
Shizume K, 516
Silberbusch J, 477
Sinhara H, 428
Sjödén G O J, 564
Sjöström L, 511
Skottner-Lundin A, 527
Smith C, 387
Smith U, 511
Smyth P P A, 15
Sogn J, 265
Sonoda T, 548

Spence C.D. 521
 Stalla G.K. 289
 Stenström G. 511
 Stimpel H. 406
 Straczek J. 43
 Suzuki Y. 428
 Svendsen P. 141
 Swart S. 330
 Sørensen O.H. 346

 Tagusagawa Y. 443
 Teijeiro J. 400
 Teisner B. 141
 Teller W.M. 227
 Terada N. 548
 Thesleff S. 336
 Thijssen J.H.H. 175, 437
 Thomas G. 338
 Thomopoulos P. 338
 Töllner U. 227
 Tolppanen E.-M. 97, 505
 Tornehave D. 141
 Touitou C. 145
 Touitou Y. 145

 Tsanaclis A.M.C. 61
 Tucci J.R. 219

 Uchimura H. 193
 Uesato T. 433
 Uitterlinden P. 21

 Vakkuri O. 152
 Vallotton M.B. 311
 Valmachino G. 109
 van der Velden P.C. 477
 Verleun T. 21
 Vescovi G. 43
 Vetter H. 317
 Vetter W. 317
 Vierhapper H. 311
 Viguier-Martinez M.C. 121
 Vora J. 330
 Vuolteenaho O. 152

 Wahlström T. 544
 Wajchenberg B.L. 61
 Waldhäusl W. 311
 Warberg J. 30
 Weetman A.P. 199

 von Werder K. 289
 Werner S. 305
 Whitworth J.A. 521
 Wiegant V.M. 21
 Wilkin T.J. 490
 Wilks J.W. 538
 Williams D. 241
 Wiqvist I. 127, 271
 Wiqvist N. 127, 271
 Wogensen L. 30
 Wolf B. 102, 209
 Wood W.G. 350
 Woodhead J.S. 199
 Wright A.D. 92

 Yamaji T. 443
 Yamamoto T. 428
 Yasuda J. 374
 Yasuda N. 158
 Yasuda Y. 158
 Yki-Järvinen H. 544
 Yoshida K. 71

 Zachmann M. 368

Insulin hypoglycaemia test guided by a glucose controlled insulin infusion system

Gert Müller-Esch, Peter Ball¹, Karen Heidbüchel,
William Graham Wood and Peter C. Scriba

*Klinik für Innere Medizin und Institut für Biochemische Endokrinologie¹,
Medizinische Hochschule, Lübeck, FRG*

Abstract. Insulin hypoglycaemia test (IHT) for assessment of hypothalamic-pituitary-adrenocortical (HPA) function in patients with pituitary tumours is usually performed by bolus injection of insulin, a procedure which includes the risk of overdosage and/or the need of repeated administration. This study describes that a glucose controlled insulin infusion system (GCIIS) permits to perform the IHT with standardized hypoglycaemia. Ten healthy volunteers and 10 patients with pituitary tumours were studied using the GCIIS (Biostator®) on static control (Mode 1:1, BI 35, QI 10, RI 20, FI 300). Insulin administration was discontinued and the GCIIS used only for monitoring of blood glucose (BG), when BG had fallen below 40 mg/dl and initial clinical symptoms for hypoglycaemia were observed. In controls, the GCIIS guided IHT achieved a sufficient degree of hypoglycaemia (BG 27.6 ± 2.0 mg/dl; mean \pm SEM) and physiological responses for GH (peak 49.4 ± 6.7 ng/ml), Prl (peak 1766 ± 614 μ U/ml), ACTH (peak 76.0 ± 8.7 pg/ml) and cortisol (peak 252 ± 15 ng/ml). The total amount of insulin given was 0.115 ± 0.012 U/kg. In the patients with pituitary tumours however, the required insulin dose varied markedly from 0.090 (pituitary insufficiency) to 0.340 U/kg (Cushing's syndrome). Minimum BG obtained was 32.5 ± 1.9 mg/dl. Partial impairment of hypothalamic-pituitary function and, in particular, patients requiring exogenous cortisol supplementation during stress, could be identified. In conclusion, special advantages of the GCIIS-guided IHT are:

1) Optimal insulin dosage with standardized hypoglycaemia due to automatic adjustment to the individual insulin sensitivity.

2) Patients' safety by earlier recognition of due insulin discontinuation as a result of continuous blood glucose analysis.

The insulin hypoglycaemia test (IHT) is a sensitive procedure for the assessment of hypothalamic-pituitary-adrenocortical (HPA) function (Faglia et al. 1973; Greenwood et al. 1966; Jenkins & Else 1968; Landon et al. 1966). It may detect subtle abnormalities of pituitary-adrenal function in patients with hypothalamic and pituitary diseases, thus identifying patients who require exogenous cortisol supplementation during severe stress such as trauma or surgery (Borst et al. 1982; Delaloye et al. 1982).

Usually, IHT is performed by bolus injection of insulin, a technique, which includes the risk of severe side effects because of overdosage. On the other hand insulin requirements can be underestimated and the subsequent need of repeated insulin administration may alter pituitary hormone responses. We therefore used a glucose controlled insulin infusion system (GCIIS) for performing the IHT on the basis of a standardized hypoglycaemia with optimal insulin delivery due to automatic adjustment to the individual insulin sensitivity.

The aim of this study was 1) to show that the GCIIS-guided IHT achieved a sufficient degree of hypoglycaemia and physiological hormone responses in healthy subjects and 2) that it permitted the assessment of HPA function in the patients with pituitary tumours studied as examples.

Presented in part at the XIVth Acta Endocrinologica Congress, Stockholm, 1983.

Supported by the Federico Foundation.

Table 1.
Clinical data of the patients studied.

Patient	Sex	Age (years)	Diagnosis
1. H. H.-B.	M	54	hormone inactive pituitary adenoma
2. P. H.	F	56	hormone inactive pituitary adenoma
3. W. W.	M	48	hormone inactive pituitary adenoma
4. E. C.	F	29	acromegaly
5. K. H.-P.	M	36	acromegaly
6. H. H.	F	45	Cushing's syndrome
7. B. W.	M	46	prolactinoma
8. F. G.	F	27	prolactinoma (MEA I)
9. P. D.	M	46	pituitary insufficiency postoperative (acromegaly)
10. M. K.	M	47	pituitary insufficiency postoperative (Cushing's syndrome)

Material and Methods

Ten healthy volunteers (4 females, 6 males, 25 ± 0.9 years, 174 ± 4 cm, 66 ± 4 kg; mean \pm SEM) and 10 patients with pituitary tumours were studied. Informed consent was obtained from the volunteers. Some clinical data of the patients are given in Table 1.

Glucose controlled insulin infusion system

The details of the GCIIS used for our study (Biostator, Life Science Instruments, Miles Laboratories, Elkhart,

USA) have been described elsewhere (Clemens et al. 1978; Fogt et al. 1978; Pfeiffer et al. 1974). The Biostator was used on static control. The following constants were chosen: BI 35, QI 10, RI 20, FI 300.

Experimental protocol

After an overnight fast, the subjects were connected to the GCIIS between 08.00 and 09.00 a.m. Feedback controlled insulin infusion (Insulin Hoechst CS, Frankfurt, FRG) was discontinued and the device was only used for blood glucose monitoring when blood glucose had




Fig. 1.

Blood glucose (BG) and insulin infusion rate (IR) during GCIIS-guided IHT in a healthy volunteer. Total amount of insulin infused by the GCIIS 0.103 U/kg.

fallen below 40 mg/dl and initial clinical symptoms of hypoglycaemia occurred (palpitations, headache, sweating, tachycardia, drowsiness) (see Fig. 1).

Venous blood samples were drawn at $\pm 0, 30, 45, 60, 90$ and 120 min, respectively, from an indwelling catheter placed in an antecubital vein. For measuring serum insulin concentration, additional samples were collected at 10 and 20 min.

Analytical methods

Serum GH (CIS), prolactin (CIS), cortisol (clinical assays, SP), ACTH (INC, without extraction), insulin (CIS) and C-peptide (Byk Mallinckrodt) were measured by radio-immunoassay.

Statistical methods

The results obtained from the healthy volunteers are expressed as mean \pm SEM.

Results

Healthy volunteers

Fig. 2 shows the mean values for blood glucose, serum insulin and serum C-peptide in the healthy volunteers. Peak insulin levels occurred between 10 and 20 min after start of feedback controlled insulin infusion. The secretion of endogenous insulin represented by serum C-peptide levels was clearly inhibited by the exogenous administered insulin, reaching its minimum 60 min after the beginning of the IHT. The intervals until discontinuation of insulin administration was 26.7 ± 1.7 min. The total amount of insulin given by the GCIS was 0.115 ± 0.012 U/kg and 4146 ± 347 mU/m² body surface, respectively. Clinical symptoms of hypoglycaemia included palpitations, sweating, headache, tachycardia and drowsiness. No severe side effects were observed and there was no need of dextrose administration.

Fig. 3 shows the serum GH, prolactin, cortisol and ACTH responses obtained in the healthy subjects. The mean basal and maximum values ($\bar{x} \pm$ SEM) observed were: GH: 2.8 ± 1.1 vs 49.4 ± 6.7 ng/ml; prolactin: 193 ± 25 vs 1766 ± 614 μ U/ml; cortisol: 100 ± 12 vs 252 ± 15 ng/ml and ACTH: 21.6 ± 2.6 vs 76.0 ± 8.7 pg/ml.

Pituitary tumour patients

Table 2 gives the results obtained from the patients with pituitary tumours expressed as basal and maximum values. The total amount of insulin




Fig. 2.

Blood glucose (BG), serum insulin and C-peptide (mean \pm SEM) during GCIS-guided IHT in 10 healthy volunteers.

given (U/kg body weight) is also shown. Minimum blood glucose was 32.5 ± 1.9 mg/dl. In the 3 patients with hormone inactive pituitary adenoma there was an impairment of GH secretion during IHT. The patients with acromegaly, when studied preoperatively, had an impaired HPA function.

They showed a blunted or deficient cortisol increase. In patient E.C. insulin requirements were markedly high; moreover, abnormal GH secretion was accompanied by elevated prolactin levels. Postoperatively, basal GH levels had returned to normal in both patients. In patient E.C., prolactin levels were now in the normal range, and insulin requirements had decreased from 0.200 to 0.106 U/kg (see Fig. 4). One of the prolactinoma patients studied (B.W.) had complete pituitary insufficiency, whereas the other one (F.G.) showed normal values and sufficient responses for GH, cortisol and ACTH. Complete impairment of the HPA axis was shown postoperatively in patients with acromegaly (P.D.) and Cushing's syndrome (M.K.). In patient H.H. (Cushing's syndrome) insulin requirements for inducing hypoglycaemia were highest (0.335 U/kg) as shown in Fig. 5.

In this patient blood glucose had fallen below 40 mg/dl after 70 min without producing distinct clinical signs of hypoglycaemia so that insulin administration had to be continued for another 10 min.

Discussion

This study indicates that the GCIIS-guided IHT is a safe and sensitive procedure in the assessment of HPA function. Using appropriate constants for the preprogrammed algorithms of the GCIIS, a sufficient degree of hypoglycaemia was achieved in healthy subjects as well as in patients with hypothalamic-pituitary disease. The range of hypogly-




Fig. 3.

Serum GH, prolactin, ACTH and cortisol responses (mean ± SEM) during GCIIS-guided IHT in 10 healthy volunteers.

Table 2.

GCIIS-guided IHT in 10 patients with pituitary tumours (numbers 1–10 refer to Table 1). Insulin requirements (infused insulin) for inducing hypoglycaemia, basal and minimal blood glucose values (BG), basal values and maximal hormone responses for GH, prolactin, ACTH and cortisol are shown. In addition, the corresponding times are mentioned (min after beginning of the test).

	Pituitary adenoma hormone inactive			Acromegaly preoperative		Acromegaly postoperative		Cushing's syndrome	Prolactinoma		Pituitary insuff. postoperative	
	1	2	3	4	5	4	5	6	7	8	9	10
Infused insulin (U/kg)	0.129	0.127	0.151	0.200	0.242	0.106	0.138	0.335	0.114	0.161	0.093	0.124
BG (mg/dl)												
Basal	90	100	83	90	81	77	80	117	78	92	88	81
Minimal	19	21	37	28	37	37	40	37	33	37	34	30
Time (min)	48	40	34	42	60	24	40	70	30	32	40	30
GH (ng/ml)												
Basal	0.6	0.7	0.5	42	78	1.1	1.5	2.3	< 0.5	1.4	0.8	1.1
Maximal	0.9	1.4	0.6	56	230	15.2	2.7	9.5	< 0.5	50	0.8	11.7
Time (min)	30	60	30	120	60	60	60	45		90		45
Prolactin (μU/ml)												
Basal	267	670	547	1470	260	177	114	252	13 640	2290	< 100	< 100
Maximal	330	1049	563	3990	359	872	117	366	15 750	2800	< 100	218
Time (min)	60	90	45	45	60	30	30	60	60	60		60
ACTH (pg/ml)												
Basal	99	38	16	36	59	27	28	26	34	25	< 35	38
Maximal	148	49	18	39	77	37	44	41	39	72	< 35	38
Time (min)	60	45	60	90	45	45	30	120	120	60		
Cortisol (ng/ml)												
Basal	120	114	20	86	39	60	30	281	< 20	103	< 20	< 20
Maximal	195	205	35	109	45	149	46	281	22	313	< 20	< 20
Time (min)	90	60	60	60	90	60	90		90	120		

caemia from 19 to 40 mg/dl (mean: 32.5 ± 1.9 mg/dl) in the pituitary tumour patients compares favourably with the bolus technique where values below 15 mg/dl are achieved more frequently. As a consequence of feedback-controlled insulin administration, an optimal insulin dosage was given according to the individual insulin sensitivity. The total amount of insulin per kg body weight in controls was comparable to the recommended dosage for performing IHT by bolus injection (Borst et al. 1982; Landon et al. 1966), but in the patients with pituitary disease studied, there was a wider range of insulin requirements (see Table 2). So, if

IHT is performed by bolus injection in patients with altered insulin sensitivity, the degree of which can not always be predicted exactly, there can be the risk of overdosage or the need of repeated injections, which is avoided by GCIIS-guided insulin administration. In the patients with partial or complete pituitary insufficiency no severe side effects were observed and there was no need of dextrose administration due to suspected insulin overdosage. On the other hand, appropriate insulin supply in the cases with decreased insulin sensitivity was guaranteed by the GCIIS. In healthy volunteers, the GCIIS-guided IHT produced phy-




Fig. 4.

Blood glucose (BG) and insulin infusion rate (IR) during GCIIS-guided IHT in a patient with acromegaly preoperatively and postoperatively.




Fig. 5.

Blood glucose (BG) and insulin infusion rate (IR) during GCIIS-guided IHT in a patient with Cushing's syndrome.
Total amount of insulin given by the GCIIS: 0.335 U/kg.

siological hormone responses for GH, prolactin, cortisol and ACTH (see Fig. 3), which were comparable to those obtained by bolus injection. In the patients with pituitary tumours, subtle or distinct impairment of HPA function could be detected (see Table 2).

In conclusion, the GCIIS-guided IHT can be recommended as a safe and sensitive procedure in the evaluation of pituitary function in patients with pituitary disease. Compared to the bolus method, it has several advantages:

1) Continuous documentation of blood glucose values.

2) Optimal insulin dosage with standardized hypoglycaemia due to automatic adjustment to the individual insulin sensitivity.

3) Patients' safety by earlier recognition of due insulin discontinuation and the need of dextrose.

Moreover, the use of the GCIIS-guided IHT may not be restricted to the assessment of HPA function in patients with pituitary disease. It seems to be of particular usefulness in studying glucose counterregulation following insulin induced hypoglycaemia in various conditions e.g. counterregulation in diabetes mellitus or hormonal and metabolic effects of different insulin preparations.

References

- Borst G C, Michenfelder H J & O'Brian J T (1982): Discordant cortisol response to exogenous ACTH and insulin-induced hypoglycemia in patients with pituitary disease. *N Engl J Med* 306: 1462–1464.
- Clemens A H, Chang P H & Myers R W (1978): The development of Biostator®, a glucose controlled insulin infusion system (GCIIS). *Horm Metab Res, Suppl* 7: 23–33.
- Delaloye J F, Gomez F & Buckhardt P (1982): Discordant cortisol response in pituitary disease. *N Engl J Med* 307: 1218.
- Faglia G, Ambrosi B, Beck-Peccoz P & Travaglini P (1973): Hypothalamic-pituitary-adrenal function in patients with pituitary tumours. *Acta Endocrinol (Copenh)* 73: 223–232.
- Fogt E J, Dodd L M, Jennings E M & Clemens A H (1978): Development and evaluation of a glucose analyzer for a glucose-controlled insulin infusion system (Biostator). *Clin Chem* 24: 1366–1372.
- Greenwood F C, Landon J & Stamp T C B (1966): The plasma sugar, free fatty acid, cortisol and growth hormone response to insulin. I. In control subjects. *J Clin Invest* 45: 429–436.
- Jenkins J S & Else W (1968): Pituitary-adrenal function tests in patients with untreated pituitary tumours. *Lancet* 2: 940–943.
- Landon J, Greenwood F C, Stamp T C B & Wynn V (1966): The plasma sugar, free fatty acid, cortisol, and growth hormone response to insulin, and the comparison of this procedure with other tests of pituitary and adrenal function. II. In patients with hypothalamic or pituitary dysfunction or anorexia nervosa. *J Clin Invest* 45: 437–449.
- Pfeiffer E F, Thum Ch & Clemens A H (1974): The artificial beta cell – a continuous control of blood sugar by external regulation of insulin infusion (glucose controlled insulin infusion system). *Horm Metab Res* 6: 339–342.

Received on August 26th, 1983.